Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Galmed Pharmaceutica (GLMD)

Galmed Pharmaceutica (GLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting PR Newswire - Mon Dec 8, 7:30AM CST

Late Breaking Abstract titled " Targeting SCD1 enhances activity of standard of care regorafenib in hepatocellular carcinoma: translational rationale for a phase 1/2 study of the combination of Aramchol...

GLMD : 1.0300 (unch)
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH PR Newswire - Thu Dec 4, 7:30AM CST

The new patent granted in South Korea is added to earlier patents already granted by the United States Patent and Trademark Office (USPTO), Europe, Canada and other jurisdictions and will expire in the...

GLMD : 1.0300 (unch)
Galmed Issues CEO Letter to Shareholders PR Newswire - Mon Dec 1, 7:30AM CST

TEL AVIV, Israel , Dec. 1, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic,...

GLMD : 1.0300 (unch)
Galmed Pharmaceuticals: Q3 Earnings Snapshot AP - Wed Nov 26, 7:56AM CST

Galmed Pharmaceuticals: Q3 Earnings Snapshot

GLMD : 1.0300 (unch)
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update PR Newswire - Wed Nov 26, 7:30AM CST

TEL AVIV, Israel , Nov. 26, 2025 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic,...

GLMD : 1.0300 (unch)
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine PR Newswire - Tue Nov 18, 7:30AM CST

The top-line results showed that bioavailability of Aramchol meglumine 400mg and 200mg granules is considerably greater, higher by 5-fold and 3-fold respectively, that of the Aramchol free acid 300mg tablets...

GLMD : 1.0300 (unch)
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro PR Newswire - Mon Nov 17, 7:30AM CST

RAMAT-GAN, Israel , Nov. 17, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases...

GLMD : 1.0300 (unch)
Galmed Pharmaceuticals: Q2 Earnings Snapshot AP - Thu Aug 28, 7:08AM CDT

Galmed Pharmaceuticals: Q2 Earnings Snapshot

GLMD : 1.0300 (unch)
Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update PR Newswire - Thu Aug 28, 7:00AM CDT

TEL AVIV, Israel , Aug. 28, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic...

GLMD : 1.0300 (unch)
Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value PR Newswire - Mon Aug 25, 6:30AM CDT

TEL AVIV, Israel , Aug. 25, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for the treatment of...

GLMD : 1.0300 (unch)

Barchart Exclusives

Will Tesla Reclaim Its Top Growth Stock Crown in 2026? Barchart - 4 minutes ago
From EV leader to AI contender, can Tesla pull it off? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot